ClinicalTrials.gg
Not yet recruitingNCT07181265Updated Sep 18, 2025

Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects

A Phase 1 interventional study of Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Jemincare · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects

02

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
03

In context

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

This study's planned enrollment of 48 is close to the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.

Browse Polycystic Kidney, Autosomal Dominant studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to participate and comply with all study procedures and restrictions, and willing to provide written to participate in the study.
  2. Healthy adult males and/or females, 18 to 45 years of age (inclusive) at the date of signed consent form. (BMI) greater than or equal to 18 and less than 32 (kg/m2) and a minimum body weight of 45 kg.
  3. The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead , all of which were determined by the investigator to be normal or not .
  4. Women of and sexually active males willing to use highly effective methods of from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm/egg for the time period specified above.

Exclusion criteria

Exclusion Criteria:

  1. Subjects having to study drug or have a history of allergies to multiple drugs, foods, or other substances
  2. History or presence of significant circulatory system, respiratory system, digestive system, blood system, urinary and reproductive system, endocrine and metabolic system, nervous system, mental system, muscular and skeletal system, skin system, lymphatic system, immune system, Otolaryngology or other related systems disease or disorder. as well as systemic or local acute or chronic infections.
  3. Subjects with dysphagia, gastrointestinal diseases, or any conditions that may affect drug absorption; such as a history of hepatobiliary and pancreatic diseases, gastrointestinal diseases, gastrointestinal surgery (except appendectomy), or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.
  4. Vital signs during the screening period meet any of the following conditions: systolic blood pressure >140 mmHg or \<90 mmHg; diastolic blood pressure >90 mmHg or \<50 mmHg (Cohort 1: diastolic blood pressure >90 mmHg or \<60 mmHg); pulse >100 beats/min or \<50 beats/min (Cohort 1: pulse >100 beats/min or \<60 beats/min); ear temperature >37.5°C or \<35°C.
  5. History of prolongation or abnormal results during screening, QTcF ≥ 450 ms for males or ≥ 470 ms for females, or QRS interval > 120 ms.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Drug-Drug interaction study of JMKX003142 and Amiodarone

    24 Subjects first administered with JMKX003142 tablets 4mg from day 1 to day 7 after breakfast. from day 12 to day 18 the subjects were adminstered with Amiodarone Hydrochloride Tablets 400 mg. from day 22 to day 28 these subjects were co-adminstered with JMKX003142 tablets 4mg and Amiodarone Hydrochloride Tablets 400 mg.

    Drug: Amiodarone Hydrochloride Tablets

  • Experimental
    Drug-Drug interaction study of JMKX003142 with Febuxostat

    24 Subjects first administered with JMKX003142 tablets 4mg from day 1 to day 7 after breakfast. from day 12 to day 18 the subjects were adminstered with Febuxostat Tablets 40 mg. from day 21 to day 27 these subjects were co-adminstered with JMKX003142 tablets 4mg and Febuxostat Tablets 40 mg.

    Drug: Febuxostat Tablets

Interventions

  • Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone

  • Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    Time frame: up to 7 days

  2. AUC0-tau

    Time frame: up tp 7 days

Secondary outcomes

  1. Tmax

    Time frame: up to 7 days

  2. AUC0-t

    Time frame: up to 7 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Apr 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartEst.
Oct 30, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07181265
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Oct 30, 2025 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Sep 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amiodarone · Febuxostat

Start the discussion